Eris Lifesciences Ltd - 540596 - Board Meeting Intimation for Consideration Of Financial Results And Interim Dividend
Eris Lifesciences board is scheduled to meet on May 20, 2026. The agenda includes approval of Q4 FY26 financial results and consideration of an interim dividend for FY27.
May 15 2026 14:05:00
Eris Lifesciences Ltd - 540596 - Announcement under Regulation 30 (LODR)-Credit Rating
India Ratings and Research affirmed Eris Lifesciences's Long-term Issuer Rating and bank facilities at 'IND AA' with a Stable outlook. This affirmation reflects sustained healthy operating performance and strong competitive position.
May 08 2026 17:05:00
Eris Lifesciences Limited
Eris Lifesciences announced a postal ballot for the appointment of Mr. Vineet Varma as an Independent Director. His tenure is proposed for five years, from March 14, 2026, to March 13, 2031, with voting concluding on March 23, 2026.
Apr 23 2026 17:04:00
Eris Lifesciences Limited
Eris Lifesciences seeks shareholder approval via postal ballot to appoint Mr. Vineet Varma as an Independent Director for five years. The e-voting period commences on April 24, 2026, and concludes on May 23, 2026.
Apr 23 2026 17:04:00
Eris Lifesciences shares decline nearly 6% after observations issued for Swiss facilities
Eris Lifesciences' manufacturing facilities in Switzerland have received observations from the Croatian health regulator following an impact inspection, indicating potential compliance issues.
Apr 21 2026 15:04:00
Eris Lifesciences Limited
Eris Lifesciences' Swiss Parenterals units 1 & 2 received non-compliance observations from HALMED after a March 9-13, 2026 inspection. The company will address these procedural issues to reinstate approvals and ensure GMP compliance, though it might delay EU-CDMO product commercialization.
Apr 20 2026 22:04:00
Read More